小金丸联合尼美舒利治疗亚急性甲状腺炎疗效观察

目的 观察小金丸联合尼美舒利治疗亚急性甲状腺炎(SAT)的临床疗效.方法 70例SAT患者随机分为2组.尼美舒利组35例,给予尼美舒利0.1 g,2次/d,口服.联合治疗组35例,给予小金丸1.2 g,2&/d,口服;尼美舒利0.1 g,2次/d,口服.2组连续用药3～4周,病情缓解后将用药剂量减半维持治疗8周.观察治疗后的疗效和停药后12周的复发率以及药物不良反应.结果 尼美舒利组与联合治疗组的治疗有效率分别为82.9%(29/35)和85.7%(30/35),体温高于39℃者2组的治疗有效率均为50.0%(3/6),尼美舒利组与联合治疗组退热时间差异无统计学意义(P>0.05),但联合治疗组对于甲状腺疼痛、压痛消退时间、第1周红细胞沉降率下降正常率、第3周甲状腺肿大或结节的回缩正常率以及停药后12周复发率,均明显优于尼美舒利组(P均<0.05).2组均无严重不良事件发生.结论 对于非高热SAT患者,选择小金丸联合尼美舒利治疗可以发挥协同治疗效应,是安全有效的治疗方案之一.

The efficacy and safety of xiaojin wan plus nimesulide in patients with subacute granulomatous thyroiditis

Objective To assess the effect of xiaojin wan plus nimesulide on patients with subacute granu-lomatoas thyroiditis(SAT). Methods 70 SAT cases were divided into nimesulide group(nimesulide 0.1 g,2/d) and combined group(nimesulide 0.1 g,2/d and xiaojin wan 1.2 g,2/d). When the patients' conditions were re-lieved after 3-4 weeks treatment,half doses of the medicines were given in two groups for 8 weeks. The efficacy,safe-ty and relapse rate after withdrawing medicines for 12 weeks were observed. Results The effective rates were 82.90% (29/35) in nimosulide group and 85.7% (30/35)in combined group, but both groups' effective rate was 50.0% (3/6) in patients with high temperature (higher than 39 ℃). The time for fever relieved in two groups were similar (P>0.05), but the thyroid pain smoothing time, normalized rates of blood sedimentation after 1 week therapy, enlarged thyroid or thyroid nodule after 3 week therapy, relapsed rate were significantly more efficacious in combined group than in nimesulide group (P<0.05). There was no severe side effects in the two groups. Conclu-sious There is a synergic effect of xiaojin wan plus nimesulide on patients with SAT, that is an effective and safe therapeutic regimen for SAT patients without high temperature.